657
Views
6
CrossRef citations to date
0
Altmetric
Review

Promising new therapies for the treatment of hypercholesterolemia

, , &
Pages 609-618 | Received 02 Oct 2015, Accepted 26 Jan 2016, Published online: 15 Feb 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Larysa Strilchuk, Giuliano Tocci, Federica Fogacci & Arrigo F. G. Cicero. (2020) An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opinion on Pharmacotherapy 21:5, pages 531-539.
Read now
Nicola Ferri, Alberto Corsini, Cesare R. Sirtori & Massimiliano Ruscica. (2017) Bococizumab for the treatment of hypercholesterolaemia. Expert Opinion on Biological Therapy 17:2, pages 237-243.
Read now

Articles from other publishers (4)

Thomas Doherty, Zhi Yao, Ahmad A.l. Khleifat, Hanz Tantiangco, Stefano Tamburin, Chris Albertyn, Lokendra Thakur, David J. Llewellyn, Neil P. Oxtoby, Ilianna Lourida, Janice M. Ranson & James A. Duce. (2023) Artificial intelligence for dementia drug discovery and trials optimization. Alzheimer's & Dementia.
Crossref
Catherine DePhillips. (2023) The Role of RNA Interference Therapeutics in Hypercholesterolemia and Implications for Practice. The Journal for Nurse Practitioners 19:6, pages 104619.
Crossref
Allison B. ReissNeal ShahDalia MuhieddineJuan ZhenJennifer YudkevichLora J. KasselmanJoshua DeLeon. (2018) PCSK9 in cholesterol metabolism: from bench to bedside. Clinical Science 132:11, pages 1135-1153.
Crossref
Karolina Obońska, Michał Kasprzak, Joanna Sikora, Ewa Obońska, Krzysztof Racki, Natalia Goździkiewicz, Magdalena Krintus & Jacek Kubica. (2017) The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials 18:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.